PRO B
The aim of the PRO B study is to examine whether the positive effects of intensified patient-reported outcomes monitoring can be transferred to the usual care of patients with metastatic breast carcinoma in Germany. PRO B is a prospective, multicentre, randomised two-arm intervention study. Depending on randomisation, patients are asked about their health status weekly (intervention arm) or every three months (control arm) via smartphone app or email. A deterioration of the values is indicated to the treating centre by an automatic alarm. The centre then decides whether to contact the patient to specify the deterioration in values and initiate measures if necessary. PRO B uses the existing certification structures of the participating breast cancer centres to link clinical data with the collected PROs.
Involved Institutions
Charité – Universitätsmedizin Berlin
German Cancer Society (DKG)
OnkoZert GmbH
BARMER
BKK·VBU
DAK-Gesundheit
Funding
Innovation Committee of The Federal Joint Committee (G-BA)
Duration
October 2020 – September 2024
Publications
see publications
Website
www.pro-b-projekt.de
Contact
Dr. rer. medic. Clara Breidenbach
PD Dr. rer. medic. Christoph Kowalski
